Anakinra in Patients With Systemic Juvenile Idiopathic Arthritis: Long-term Safety From the Pharmachild Registry.
Gabriella GiancaneRiccardo PapaSebastiaan VastertFrancesca BagnascoJoost F SwartPierre Quartier Dit MaireJordi AntónSylvia KamphuisHelga SannerMia B GlerupFabrizio De BenedettiElena TsitsamiAgustin RemesalEstefania MorenoJaime De InocencioCharlotte MyrupChiara PallottiIsabelle Koné-PautKarin Franck-LarssonHåkan MalmströmSusanna CederholmAngela PistorioNico WulffraatNicolino Rupertonull nullPublished in: The Journal of rheumatology (2022)
The results of the present study confirm the long-term safety profile of anakinra in patients with sJIA and demonstrate an overall decreasing incidence of AEs over time. [ClinicalTrials.gov: NCT01399281 and NCT03932344].